English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We comparatively assessed the overall efficacies of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy for previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer in Asians through a meta-analysis of relevant phase-3 trials. The primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS), respectively. Pooled estimates were calculated as hazard ratios (HRs) with 95% con dence intervals (CIs). Seven studies on EGFR-TKIs met the inclusion criteria for this study. The HRs and 95% CIs for OS and PFS for EGFR-TKIs, relative to chemotherapy, were 0.98 (0.77-1.24) and 0.32 (0.24-0.43), respectively. We found no difference in overall ef cacy between EGFR-TKIs and chemotherapy in terms of OS, although the median PFS with EGFR-TKI was superior to that with chemotherapy among Asians with previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer (UMIN ID : UMIN28424).

EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis